1-hexadecyl-3-methylimidazolium bromide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 2846928 |
| CHEMBL ID | 1448592 |
| SCHEMBL ID | 2530782 |
| MeSH ID | M0520656 |
| Synonym |
|---|
| HMS2596G08 |
| MLS001049340 |
| 3-hexadecyl-1-methyl-3h-imidazol-1-ium |
| smr000427322 |
| 132361-22-9 |
| HMS2801M22 |
| 1-hexadecyl-3-methylimidazolium bromide |
| REGID_FOR_CID_2846928 |
| SCHEMBL2530782 |
| 1-hexadecyl-3-methylimidazol-3-ium;bromide |
| CHEMBL1448592 |
| 3-hexadecyl-1-methyl-1h-imidazol-3-ium bromide |
| AKOS030227964 |
| QPERNWXRUSFVPU-UHFFFAOYSA-M |
| 1-methyl-3-hexadecylimidazolium bromide |
| 1-methyl-3-cetylimidazolium bromide |
| mfcd19442853 |
| 1-hexadecyl-3-methyl-1h-imidazol-3-ium bromide |
| ZB1680 |
| D83632 |
| CS-0152194 |
| 3-hexadecyl-1-methyl-1h-imidazol-3-iumbromide |
| c20h39brn2 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 35.7168 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 42.8000 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 71.2642 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 4.9490 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| WRN | Homo sapiens (human) | Potency | 7.0795 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 28.9342 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 8.8116 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 40.0749 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.2986 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 28.9342 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 11.2202 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 12.5893 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 11.9047 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| IDH1 | Homo sapiens (human) | Potency | 17.3582 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 79.4328 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 2.8184 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 58.3344 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 6.6865 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 11.2202 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 12.5893 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 58.3100 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 19.6221 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| enteropeptidase precursor | Homo sapiens (human) | Potency | 10.0000 | 3.1623 | 8.1369 | 10.0000 | AID493169 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 22.8340 | 0.6561 | 9.4520 | 25.1189 | AID493168; AID493170 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.5849 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| snurportin-1 | Homo sapiens (human) | Potency | 58.3100 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.5849 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.5849 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.5849 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.0876 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 26.2607 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 12.6728 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 5.0119 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 25.1189 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 10.0000 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 18.4938 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 70.7946 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| calpain II, partial | Sus scrofa (pig) | IC50 (µMol) | 11.3875 | 1.7742 | 4.9338 | 7.7087 | AID1420 |
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 (µMol) | 60.8250 | 0.0375 | 18.6232 | 53.2000 | AID588524; AID588538 |
| XBP1 | Homo sapiens (human) | IC50 (µMol) | 2.2100 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
| neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 (µMol) | 37.5900 | 0.3900 | 6.5441 | 29.1200 | AID1275 |
| phospholipase A2 precursor | Homo sapiens (human) | IC50 (µMol) | 5.7800 | 1.0200 | 9.0025 | 15.2000 | AID588400 |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0256 | 16.5070 | 52.8000 | AID588574 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.8730 | 10.7219 | 78.4000 | AID493155 |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0256 | 20.3235 | 74.3000 | AID588574 |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 (µMol) | 12.9500 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 0.8600 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 12.9500 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| cysteine protease ATG4B isoform a | Homo sapiens (human) | IC50 (µMol) | 4.4700 | 1.2500 | 10.6632 | 19.1000 | AID504756 |
| putative polyprotein | IC50 (µMol) | 11.7795 | 0.2508 | 3.8283 | 8.4620 | AID720577; AID720578 | |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| serine/threonine-protein kinase 33 isoform a | Homo sapiens (human) | EC50 (µMol) | 120.0000 | 0.7691 | 14.6096 | 44.8900 | AID2821 |
| recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 10.7700 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 39.9798 | 0.0600 | 8.9128 | 130.5170 | AID1902; AID1914 |
| POsterior Segregation | Caenorhabditis elegans | EC50 (µMol) | 300.0000 | 2.2010 | 47.1808 | 186.6810 | AID1964 |
| Estrogen receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 77.9860 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | EC50 (µMol) | 300.0000 | 0.0820 | 31.0243 | 168.9080 | AID1960 |
| Estrogen receptor beta | Rattus norvegicus (Norway rat) | EC50 (µMol) | 77.9860 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
| Zinc finger protein mex-5 | Caenorhabditis elegans | EC50 (µMol) | 300.0000 | 0.0820 | 33.5679 | 168.9080 | AID1960 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 3.4810 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 5.3823 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 2.8920 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| hypothetical protein CAALFM_CR05890CA | Candida albicans SC5314 | AC50 | 54.7000 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| H3 histone acetyltransferase | Candida albicans SC5314 | AC50 | 54.7000 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||